Literature DB >> 26527031

Can tumor regression grade influence survival outcome in ypT3 rectal cancer?

L Shen1,2, L Wang2,3, G Li1,2, H Zhang1,2, L Liang1,2, M Fan1,2, Y Wu1,2, W Deng1,2, W Sheng2,3, J Zhu1,2, Z Zhang4,5.   

Abstract

PURPOSE: Locally advanced rectal cancer (LARC) patients achieving ypT3 status following neoadjuvant chemoradiation are considered to have poor response with minimal downstaging. However, residual cancer cell amounts vary in the subserosa/perirectal fat. Tumor regression grading (TRG) is an evaluation method based on the proportion of fibrosis and residual cancer cells. The aim of this study is to assess the influence of TRG in ypT3 rectal cancer patients who received neoadjuvant chemoradiation.
METHODS: We retrospectively reviewed 325 LARC patients who received neoadjuvant chemoradiation and surgery. TRG scores were recorded by two independent pathologists. Among these patients, 143 were staged as ypT3. We analyzed TRG and other clinicopathological factors and their relationship with survival outcome including overall survival (OS) and disease-free survival (DFS).
RESULTS: Among 143 ypT3 patients, 44 (30.8 %) were TRG1, 84 (58.7 %) were TRG2 and 15 (10.5 %) were TRG3. Seventy-nine (55.3 %) of these patients had metastatic lymph nodes. In univariate analysis, TRG was not associated with DFS (TRG2 vs TRG1, P = 0.852; TRG3 vs TRG1, P = 0.593) or OS (TRG2 vs TRG1, P = 0.977; TRG3 vs TRG1, P = 0.665). Palliative surgery (HR 3.845; 95 % CI 1.670-8.857; P = 0.002) and metastatic lymph nodes after surgery (HR 5.894; 95 % CI 1.142-3.48; P = 0.015) were significantly associated with decreased DFS, while palliative surgery was the only factor associated with worse OS (HR 6.011; 95 % CI 2.150-16.810; P = 0.001). Palliative surgery (HR 3.923; 95 % CI 1.696-9.073; P = 0.001) and metastatic lymph nodes (HR 2.011; 95 % CI 1.152-3.512; P = 0.014) also showed prognostic significance for DFS in multivariate analysis.
CONCLUSIONS: Residual cancer cells evaluated by TRG score after neoadjuvant chemoradiation do not influence survival outcome in ypT3 rectal cancer patients. However, lymph node status is a significant prognostic factor in ypT3 patients.

Entities:  

Keywords:  Rectal cancer; Tumor regression grade (TRG); ypT3

Mesh:

Year:  2015        PMID: 26527031     DOI: 10.1007/s12094-015-1419-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  30 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis.

Authors:  Luigi Zorcolo; Alan S Rosman; Angelo Restivo; Michele Pisano; Giuseppe R Nigri; Alessandro Fancellu; Marcovalerio Melis
Journal:  Ann Surg Oncol       Date:  2012-03-21       Impact factor: 5.344

3.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

Review 4.  MR imaging for preoperative evaluation of primary rectal cancer: practical considerations.

Authors:  Harmeet Kaur; Haesun Choi; Y Nancy You; Gaiane M Rauch; Corey T Jensen; Ping Hou; George J Chang; John M Skibber; Randy D Ernst
Journal:  Radiographics       Date:  2012 Mar-Apr       Impact factor: 5.333

5.  Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.

Authors: 
Journal:  Radiology       Date:  2007-02-28       Impact factor: 11.105

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

8.  Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation?

Authors:  Vijai Simha; Rakesh Kapoor; Rajesh Gupta; Amit Bahl; Ritambhara Nada
Journal:  J Gastrointest Oncol       Date:  2014-08

Review 9.  The RAS signal transduction pathway and its role in radiation sensitivity.

Authors:  W Gillies McKenna; Ruth J Muschel; Anjali K Gupta; Stephen M Hahn; Eric J Bernhard
Journal:  Oncogene       Date:  2003-09-01       Impact factor: 9.867

10.  Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer.

Authors:  Rumi Shin; Seung-Yong Jeong; Hong Yeol Yoo; Kyu Joo Park; Seung Chul Heo; Gyeong Hoon Kang; Woo Ho Kim; Jae-Gahb Park
Journal:  Dis Colon Rectum       Date:  2012-12       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.